A Phase 3 interventional study of Bosentan and Matching placebo in Persistent Pulmonary Hypertension of the Newborn, sponsored by Actelion. Terminated. Open to participants aged 12 Hours to 7 Days. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The AC-052-391-study is a phase 3 study to investigate whether adding bosentan to inhaled nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a supporting and safe therapy and to evaluate the pharmacokinetics of bosentan and its metabolites.
40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.
This study's enrollment of 23 is below the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.
Browse Persistent Fetal Circulation Syndrome studies →Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bosentan
Drug: Bosentan
Matching placebo
Drug: Matching placebo
2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
Also known as: Tracleer
twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
Percentage of Patients With Treatment Failure
Treatment failure was defined as the need for extra corporeal membrane oxygenation or initiation of alternative pulmonary vasodilator treatment
Time frame: From baseline to up to 21 days
Time to Complete Weaning From iNO
Calculated from the time from first study drug administration to complete weaning from iNO. Weaning from iNO was considered complete if there was no requirement for the re-initiation of iNO within 24 h after stopping
Time frame: From baseline to up to 21 days
Time to Complete Weaning From Mechanical Ventilation
Calculated from the time from first study drug administration to complete weaning from mechanical ventilation
Time frame: From baseline to up to 21 days
Percentage of Patients Requiring Re-initiation of iNO Therapy
Re-initiation of iNO therapy following weaning from iNO therapy
Time frame: From baseline to up to 21 days
Percentage of Patients With Pulmonary Hypertension (PH) at End of Treatment
The presence of PH was assessed by echocardiography. PH was reported as 'present' if at least one of the following criteria was met: * Shunt through ductus arteriosus was either 'predominant right to left' or 'bidirectional' * Shunt through foramen ovale was either 'predominant right to left' or 'bidirectional' * Marked right ventricular dilation was ticked 'present' * Paradoxical shift of intraventricular septum was ticked 'present' * Right ventricular systolic pressure (mmHg) was \> 2/3 of the reported systemic blood pressure
Time frame: From baseline to up to 14 days
Change in Oxygenation Index (OI) From Baseline to 3 Hours Following Study Drug Administration
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
Time frame: 3 hours
Change in Oxygenation Index (OI) From Baseline to 5 Hours Following Study Drug Administration
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
Time frame: 5 hours
Change in Oxygenation Index (OI) From Baseline to 12 Hours Following Study Drug Administration
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
Time frame: 12 hours
Change in Oxygenation Index (OI) From Baseline to 24 Hours Following Study Drug Administration
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
Time frame: 24 hours
Change in Oxygenation Index (OI) From Baseline to 48 Hours Following Study Drug Administration
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
Time frame: 48 hours
Change in Oxygenation Index (OI) From Baseline to 72 Hours Following Study Drug Administration
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
Time frame: 72 hours
Change in Arterial Blood Gas (ABG) pH From Baseline to 72 Hours Following Study Drug Administration
pH was determined in arterial blood samples at baseline and 72 h after the first study drug administration
Time frame: 72 hours
Change in Arterial Blood Oxygen Saturation (SaO2) From Baseline to 72 Hours Following Study Drug Administration
SaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration
Time frame: 72 hours
Change in Partial Pressure of Oxygen (PaO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration
PaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration
Time frame: 72 hours
Change in Partial Pressure of Carbon Dioxide (PaCO2) in Arterial Blood From Baseline to 72 Hours Following Study Drug Administration
PaCO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration
Time frame: 72 hours
Change in Pre-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration
Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration
Time frame: 72 hours
Change in Post-ductal Peripheral Oxygen Saturation (SpO2) From Baseline to 72 Hours Following Study Drug Administration
Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration
Time frame: 72 hours
Change in Fraction of Inspired Oxygen (FiO2) From Baseline to 72 Hours Following Study Drug Administration
FiO2 was determined according to each study centers' standard procedure at baseline and 72 h after the first study drug administration
Time frame: 72 hours
Maximum Whole Blood Concentration (Cmax) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Cmax was obtained directly from the measured concentrations. Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.
Time frame: up to 12 hours
Cmax for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 5
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Cmax obtained directly from the measured concentrations . Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.
Time frame: 12 hours
Time to Maximum Whole Blood Concentration (Tmax) for Bosentan on Day 1
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
Time frame: up to 12 hours
Tmax for Ro 47-8634 on Day 1
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
Time frame: up to 12 hours
Tmax for Ro 48-5033 on Day 1
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
Time frame: up to 12 hours
Tmax for Ro 64-1056 on Day 1
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
Time frame: up to 12 hours
Tmax for Bosentan on Day 5
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
Time frame: 12 hours
Tmax for Ro 47-8634 on Day 5
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
Time frame: 12 hours
Tmax for Ro 48-5033 on Day 5
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
Time frame: 12 hours
Tmax for Ro 64-1056 on Day 5
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
Time frame: 12 hours
Area Under the Concentration-time Curve Over a Period of 12 h (AUC0-12 Day 1)) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056 on Day 1
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-12 Day 1 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.
Time frame: 12 hours
Area Under the Concentration-time Curve Over a Dosing Interval at Steady State on Day 5 (AUCtau) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUCtau Day 5 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.
Time frame: 5 days
Area Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 1 (AUC0-24C Day 1) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 1 was calculated as a multiple of AUC0-12, (2 × AUC0-12 for 2 times daily dosing) corrected to 2 mg/kg.
Time frame: 24 hours
Area Under the Concentration-time Curve Over a Period of 24 h (Dose-corrected to 2 mg/kg) on Day 5 (AUC0-24C Day 5) for Bosentan and Its Metabolites, Ro 47-8634, Ro 48-5033, and Ro 64-1056
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 5 was calculated as a multiple of AUCtau, (2 × AUCtau for 2 times daily dosing) corrected to 2 mg/kg.
Time frame: 24 hours
Accumulation Index (AI) for Bosentan
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Days 1 and 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AI was calculated as the ratio AUCtau /AUC0-12 for the subjects having PK samples collected on Day 1 and Day 5 and with AUC0-12 \> 0 ng.h/mL.
Time frame: 5 days
First patient, first visit was 8 December 2011 and last patient, last visit was 5 December 2013. The investigational sites were tertiary care centers with neonatal intensive care unit facilities at which inhaled nitric oxide (iNO) was used as standard of care for persistent pulmonary hypertension of the newborn (PPHN).
| Milestone | Bosentan | Placebo |
|---|---|---|
| Started | 13 | 8 |
| Completed | 13 | 8 |
| Not completed | 0 | 0 |
Treatment failure was defined as the need for extra corporeal membrane oxygenation or initiation of alternative pulmonary vasodilator treatment
| percentage of participants | Bosentan | Placebo |
|---|---|---|
| Percentage of Patients With Treatment Failure | 7.7 | 0 |
Calculated from the time from first study drug administration to complete weaning from iNO. Weaning from iNO was considered complete if there was no requirement for the re-initiation of iNO within 24 h after stopping
| days | Bosentan | Placebo |
|---|---|---|
| Time to Complete Weaning From iNO | 3.7 (1.17 to 6.95) | 2.9 (1.26 to 4.23) |
Calculated from the time from first study drug administration to complete weaning from mechanical ventilation
| days | Bosentan | Placebo |
|---|---|---|
| Time to Complete Weaning From Mechanical Ventilation | 10.8 (3.21 to 12.21) | 8.6 (3.71 to 9.66) |
Re-initiation of iNO therapy following weaning from iNO therapy
| percentage of participants | Bosentan | Placebo |
|---|---|---|
| Percentage of Patients Requiring Re-initiation of iNO Therapy | 0 | 0 |
The presence of PH was assessed by echocardiography. PH was reported as 'present' if at least one of the following criteria was met: * Shunt through ductus arteriosus was either 'predominant right to left' or 'bidirectional' * Shunt through foramen ovale was either 'predominant right to left' or 'bidirectional' * Marked right ventricular dilation was ticked 'present' * Paradoxical shift of intraventricular septum was ticked 'present' * Right ventricular systolic pressure (mmHg) was \> 2/3 of the reported systemic blood pressure
| percentage of participants | Bosentan | Placebo |
|---|---|---|
| Percentage of Patients With Pulmonary Hypertension (PH) at End of Treatment | 41.7 | 37.5 |
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
| oxygenation index | Bosentan | Placebo |
|---|---|---|
| Baseline | 18.3 (8.2 to 35.4) | 13.2 (7.9 to 39.4) |
| 3 hours | 17.3 (6.9 to 33.3) | 13.0 (8.5 to 42.9) |
| Change from baseline | -1.6 (-5.1 to 3.3) | 1.1 (-6.1 to 6.1) |
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
| oxygenation index | Bosentan | Placebo |
|---|---|---|
| Baseline | 18.3 (8.2 to 35.4) | 13.2 (7.9 to 39.4) |
| 5 hours | 16.7 (7.9 to 36.7) | 13.3 (6.7 to 28.6) |
| Change from baseline | -0.9 (-4.7 to 4.5) | -5.6 (-7.5 to 15.7) |
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
| oxygenation index | Bosentan | Placebo |
|---|---|---|
| Baseline | 18.3 (8.2 to 35.4) | 13.2 (7.9 to 39.4) |
| 12 hours | 14.3 (8.3 to 26.7) | 11.1 (4.9 to 19.6) |
| Change from baseline | -0.8 (-12.9 to 2.8) | -3.9 (-14.6 to 12.5) |
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
| oxygenation index | Bosentan | Placebo |
|---|---|---|
| Baseline | 18.3 (8.2 to 35.4) | 13.2 (7.9 to 39.4) |
| 24 hours | 13.1 (6.5 to 32.9) | 11.8 (5.2 to 26.4) |
| Change from baseline | -4.9 (-17.0 to 1.1) | -6.9 (-9.9 to 19.4) |
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
| oxygenation index | Bosentan | Placebo |
|---|---|---|
| Baseline | 19.4 (8.2 to 35.4) | 13.2 (7.9 to 39.4) |
| 48 hours | 11.5 (4.7 to 21.0) | 3.8 (2.5 to 10.8) |
| Change from baseline | -4.9 (-15.5 to -2.1) | -9.9 (-18.0 to 3.4) |
The change in OI from baseline following study drug administration was determined. OI was calculated as the mean airway pressure multiplied by the fraction of inspired oxygen (expressed in %), and the product was divided by the partial pressure of oxygen in arterial blood.
| oxygenation index | Bosentan | Placebo |
|---|---|---|
| Baseline | 19.4 (8.2 to 35.4) | 13.2 (7.9 to 39.4) |
| 72 hours | 6.7 (4.2 to 17.0) | 3.9 (3.7 to 10.8) |
| Change from baseline | -8.9 (-23.1 to -1.8) | -9.4 (-17.7 to 2.2) |
pH was determined in arterial blood samples at baseline and 72 h after the first study drug administration
| pH | Bosentan | Placebo |
|---|---|---|
| Baseline | 7.37 (7.30 to 7.43) | 7.31 (7.21 to 7.49) |
| 72 hours | 7.37 (7.36 to 7.43) | 7.36 (7.30 to 7.39) |
| Change from baseline | 0.04 (-0.06 to 0.07) | 0.02 (-0.09 to 0.19) |
SaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration
| percentage saturation | Bosentan | Placebo |
|---|---|---|
| Baseline | 95.0 (92.0 to 99.0) | 95.5 (89.0 to 99.0) |
| 72 hours | 98.0 (95.0 to 100.0) | 97.0 (93.0 to 100.0) |
| Change from baseline | 1.0 (0.0 to 8.0) | 0.0 (-4.0 to 21.0) |
PaO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration
| mm Hg | Bosentan | Placebo |
|---|---|---|
| Baseline | 61.0 (53.0 to 132.0) | 69.5 (46.0 to 111.0) |
| 72 hours | 81.0 (61.0 to 104.0) | 81.5 (56.0 to 187.0) |
| Change from baseline | 18.0 (-13.0 to 32.0) | 6.0 (-12.0 to 115.0) |
PaCO2 was determined in arterial blood samples at baseline and 72 h after the first study drug administration
| mm Hg | Bosentan | Placebo |
|---|---|---|
| Baseline | 40.5 (31.0 to 47.0) | 46.0 (35.0 to 57.0) |
| 72 hours | 45.5 (36.0 to 49.0) | 46.0 (41.0 to 64.0) |
| Change from baseline | 6.0 (-1.0 to 12.0) | 8.0 (-8.0 to 21.0) |
Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration
| percentage saturation | Bosentan | Placebo |
|---|---|---|
| Baseline | 95.00 (91.00 to 99.00) | 97.00 (91.00 to 99.00) |
| 72 hours | 96.00 (93.00 to 100.00) | 96.00 (85.00 to 100.00) |
| Change from baseline | 0.50 (-2.00 to 2.00) | -1.00 (-10.00 to 2.00) |
Simultaneous pre- (right hand) and post-ductal (lower extremities) SpO2 were measured using pulse oximetry device at baseline and 72 h after the first study drug administration
| percentage saturation | Bosentan | Placebo |
|---|---|---|
| Baseline | 96.5 (92.0 to 99.0) | 96.0 (89.0 to 98.0) |
| 72 hours | 95.5 (94.0 to 99.0) | 97.5 (95.0 to 100.0) |
| Change from baseline | 0.0 (-2.0 to 3.0) | 2.0 (1.0 to 12.0) |
FiO2 was determined according to each study centers' standard procedure at baseline and 72 h after the first study drug administration
| percentage of oxygen | Bosentan | Placebo |
|---|---|---|
| Baseline | 90.0 (62.0 to 97.0) | 78.0 (60.0 to 100.0) |
| 72 hours | 51.5 (28.0 to 60.0) | 40.0 (25.0 to 60.0) |
| Change from baseline | -33.5 (-50.0 to -15.0) | -35.5 (-60.0 to 0.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Cmax was obtained directly from the measured concentrations. Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.
| ng/mL | Bosentan |
|---|---|
| Bosentan | 30.1 (2.4 to 372.2) |
| Ro 47-8634 | 0.1 (0.0 to 1.1) |
| Ro 48-5033 | 0.6 (0.0 to 18.3) |
| Ro 64-1056 | 0.9 (0.0 to 16.2) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Cmax obtained directly from the measured concentrations . Cmax was corrected to a dose of 2 mg/kg bosentan (Cmaxc). The target dose was 2 mg/kg. However, as the smallest dose unit was 8 mg (quarter of a tablet), it was not possible to achieve the exact target dose in all patients. Therefore, Cmax was divided by the actual dose (in mg/kg) and multiplied by 2 mg/kg.
| ng/mL | Bosentan |
|---|---|
| Bosentan | 880.0 (339.2 to 2282.7) |
| Ro 47-8634 | 24.9 (9.0 to 69.1) |
| Ro 48-5033 | 292.3 (115.8 to 738.1) |
| Ro 64-1056 | 136.0 (77.4 to 238.8) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Time to Maximum Whole Blood Concentration (Tmax) for Bosentan on Day 1 | 12.0 (7.5 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Tmax for Ro 47-8634 on Day 1 | 12.0 (7.5 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Tmax for Ro 48-5033 on Day 1 | 12.0 (12.0 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Tmax for Ro 64-1056 on Day 1 | 12 (0.5 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Tmax for Bosentan on Day 5 | 7.5 (0.8 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Tmax for Ro 47-8634 on Day 5 | 6.5 (0.8 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Tmax for Ro 48-5033 on Day 5 | 7.5 (0.8 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Tmax was obtained directly from the measured concentrations.
| hours | Bosentan |
|---|---|
| Tmax for Ro 64-1056 on Day 5 | 12.0 (7.5 to 12.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-12 Day 1 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.
| h*ng/mL | Bosentan |
|---|---|
| Bosentan | 163.9 (9.6 to 2795.4) |
| Ro 47-8634 | 0.1 (0.0 to 3.7) |
| Ro 48-5033 | 1.4 (0.0 to 69.9) |
| Ro 64-1056 | 2.2 (0.1 to 64.1) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUCtau Day 5 was calculated according to the trapezoidal rule using the measured concentration-time values above the limit of quantification.
| h*ng/mL | Bosentan |
|---|---|
| Bosentan | 6165.4 (2429.6 to 15645.3) |
| Ro 47-8634 | 217.3 (75.3 to 626.8) |
| Ro 48-5033 | 2839.5 (1155.2 to 6979.2) |
| Ro 64-1056 | 1321.7 (729.5 to 2395.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Day 1. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 1 was calculated as a multiple of AUC0-12, (2 × AUC0-12 for 2 times daily dosing) corrected to 2 mg/kg.
| h*ng/mL | Bosentan |
|---|---|
| Bosentan | 287.5 (15.0 to 5504.7) |
| Ro 47-8634 | 0.1 (0.0 to 6.1) |
| Ro 48-5033 | 2.0 (0.0 to 125.8) |
| Ro 64-1056 | 3.4 (0.1 to 120.8) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to study drug administration and at 0.5, 1, 2, 3, 7.5, and 12 hours post-dose on Day 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AUC0-24C Day 5 was calculated as a multiple of AUCtau, (2 × AUCtau for 2 times daily dosing) corrected to 2 mg/kg.
| h*ng/mL | Bosentan |
|---|---|
| Bosentan | 11530.2 (4507.0 to 29497.5) |
| Ro 47-8634 | 406.3 (139.8 to 1180.9) |
| Ro 48-5033 | 5310.3 (2184.4 to 12908.9) |
| Ro 64-1056 | 2471.9 (1386.1 to 4408.0) |
Concentrations were measured directly in dried blood spot samples scheduled to be taken immediately prior to first study drug administration and at 0.5, 1, 2, 3, 7.5 and 12 hours post-dose on Days 1 and 5. Pharmacokinetic parameters were determined on the basis of scheduled blood sampling time points using non-compartmental analysis. Actual blood sampling times were used only if there was a deviation of more than 5% from the scheduled times. AI was calculated as the ratio AUCtau /AUC0-12 for the subjects having PK samples collected on Day 1 and Day 5 and with AUC0-12 \> 0 ng.h/mL.
| accumulation index | Bosentan |
|---|---|
| Accumulation Index (AI) for Bosentan | 61.6 (0.5 to 7813.9) |
Collected over Up to 21 Days, plus up to 60 days after end of treatment for serious adverse events. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan | — | 2/13 (15.4%) | 9/13 (69.2%) |
| Placebo | — | 3/8 (37.5%) | 2/8 (25%) |
| Event | Bosentan | Placebo |
|---|---|---|
| PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders | 0/13 | 2/8 |
| SEPSISInfections and infestations | 0/13 | 1/8 |
| HEPATITISHepatobiliary disorders | 1/13 | 0/8 |
| METABOLIC ACIDOSISMetabolism and nutrition disorders | 1/13 | 0/8 |
| HYPERCAPNIARespiratory, thoracic and mediastinal disorders | 1/13 | 0/8 |
| CIRCULATORY COLLAPSEVascular disorders | 1/13 | 0/8 |
| Event | Bosentan | Placebo |
|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 3/13 | 1/8 |
| GENERALISED OEDEMAGeneral disorders | 3/13 | 0/8 |
| VOMITINGGastrointestinal disorders | 2/13 | 0/8 |
| COAGULOPATHYBlood and lymphatic system disorders | 1/13 | 1/8 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 0/13 | 1/8 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 0/13 | 1/8 |
| HYPOPHOSPHATAEMIAMetabolism and nutrition disorders | 0/13 | 1/8 |
| METABOLIC ACIDOSISMetabolism and nutrition disorders | 0/13 | 1/8 |
| BILIRUBIN CONJUGATED INCREASEDInvestigations | 1/13 | 0/8 |
| BODY TEMPERATURE INCREASEDInvestigations | 1/13 | 0/8 |
Randomized and treated patients
| Age, Continuous(days) | Bosentan | Placebo | Total |
|---|---|---|---|
| Median | 1.4 (0.6 to 5.6) | 1.7 (0.6 to 5.9) | 1.4 (0.6 to 5.9) |
| Sex: Female, Male(Participants) | Bosentan | Placebo | Total |
|---|---|---|---|
| Female | 9 | 6 | 15 |
| Male | 4 | 2 | 6 |
| Race/Ethnicity, Customized(participants) | Bosentan | Placebo | Total |
|---|---|---|---|
| Caucasian/white | 11 | 6 | 17 |
| Asian | 1 | 0 | 1 |
| Hispanic | 1 | 1 | 2 |
| Other | 0 | 1 | 1 |
| Region of Enrollment(participants) | Bosentan | Placebo | Total |
|---|---|---|---|
| Czech Republic | 1 | 1 | 2 |
| France | 1 | 0 | 1 |
| Korea, Republic of | 1 | 0 | 1 |
| Poland | 5 | 3 | 8 |
| United Kingdom | 4 | 2 | 6 |
| United States | 1 | 2 | 3 |
| Gestational age(weeks) | Bosentan | Placebo | Total |
|---|---|---|---|
| Median | 40.0 (36.0 to 41.0) | 38.5 (36.0 to 42.0) | 39.0 (36.0 to 42.0) |
No study locations are listed for this record.
The record gives a start of Dec 2011, a primary completion of Dec 2013 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan
Persistent Fetal Circulation Syndrome →